Quarterly Result27 Oct 2025, 04:24 pm
Jubilant Ingrevia Reports 18% Increase in Profit After Tax in Q2 FY26
AI Summary
Jubilant Ingrevia Ltd reported an 8% year-over-year growth in EBITDA and an impressive 18% increase in Profit After Tax for the second quarter of this fiscal year. The Speciality Chemicals segment drove the growth momentum with double-digit YoY revenue growth. The Nutrition business maintained steady volume growth, and the Chemical Intermediates business clocked highest quarterly sales in the last six quarters. Despite challenging market conditions, the company grew revenues on the back of growth in volume-market-share and maintained profitability.
Key Highlights
- Speciality Chemicals segment reported 25%+ margins, driven by strong performance in Fine Chemicals and CDMO sales
- Added 10+ new molecules in CDMO/Fine chemicals portfolio, contributing 1200cr+ of peak annual revenues in coming years
- Nutrition and Health Solutions business segment grew volumes on YoY basis, with steady revenue despite lower pricing
- Chemical Intermediates segment reported highest quarterly revenue and volumes in last six quarters
- Expected part-recovery in the Acetyls portfolio and on track to start serving a major CDMO order in early 2026